Mounjaro
Also called tirzepatide injection, Mounjaro pen, Zepbound.
By Dr Chad Okay4 min read
Mounjaro is the brand name Eli Lilly uses for tirzepatide injections, taken once a week. It is a dual agonist that activates both GLP-1 and GIP receptors. In the UK it is licensed for type 2 diabetes and, separately, for weight management. In trials it produces slightly more weight loss than semaglutide (Wegovy), with similar gut side effects.
What Mounjaro is
Mounjaro is tirzepatide, a single molecule that binds to two different gut hormone receptors at once: GLP-1 (the same target as semaglutide) and GIP. Both hormones are released by the small intestine after meals. Activating both is thought to amplify the effects on insulin release, gastric emptying, and appetite. In the US the same drug is sold for weight loss under the brand Zepbound.
How it compares to Wegovy
- Average weight loss in the SURMOUNT-1 trial: 22.5% at 72 weeks on the 15 mg dose (NEJM headline; NICE cites 20.9% under a stricter treatment-regimen estimand). The 2025 SURMOUNT-5 head-to-head trial showed tirzepatide 20.2% vs semaglutide 13.7% at 72 weeks.
- Side effect profile is similar: nausea, constipation, reflux, fatigue.
- Dose schedule is similar: a slow titration over 4 to 5 months.
- Both are weekly injections. The pens look almost identical.
- In the UK, NICE recommends tirzepatide for weight management in eligible adults; it can be used in primary care or specialist weight management services.
The dose ladder
- Week 1 to 4: 2.5 mg weekly. Starter dose, tolerance only.
- Week 5 to 8: 5 mg weekly. First meaningful dose.
- Week 9 to 12: 7.5 mg weekly.
- Week 13 to 16: 10 mg weekly.
- Week 17 to 20: 12.5 mg weekly.
- Week 21 onwards: 15 mg weekly maintenance dose.
Side effects
- Nausea, peaking after each dose increase and usually settling in 1 to 2 weeks.
- Constipation. Slowed gut transit is part of the mechanism. It was a frequent gastrointestinal side effect across the tirzepatide doses in the SURMOUNT trials. Hydration and fibre matter.
- Diarrhoea in a minority, usually early on.
- Reflux from food sitting longer in the stomach.
- Injection-site reactions: small bumps or itching, almost always self-resolving.
- Rare but serious: pancreatitis, gallstones, severe gastroparesis. Severe, persistent abdominal pain needs a doctor the same day, not a wait-and-see approach (see below).
If something feels wrong
This entry is reference information, not medical guidance. Your doctor and pharmacist know you and your medicine; if anything about how you feel worries you, speak to them promptly, and if you ever feel seriously unwell, treat it as an emergency. The medicine's own patient information leaflet carries the important safety information and is worth reading in full.
What is still unknown
The dedicated cardiovascular outcomes trial in type 2 diabetes (SURPASS-CVOT, published December 2025) found tirzepatide non-inferior to dulaglutide for major cardiovascular events. Long-term safety in people without diabetes who take it for weight management is less well characterised than for semaglutide. Both drugs are extremely new in the population history of medication, which is worth keeping in mind when reading anecdote-driven press coverage.
Common questions
Different molecules. Tirzepatide (Mounjaro) tends to produce slightly more weight loss in head-to-head trials. Semaglutide (Ozempic, Wegovy) has more years of post-launch data. The right choice depends on what the drug is being prescribed for, supply availability in the UK, and how each person tolerates side effects.
Sources
- 1Mounjaro KwikPen 15mg solution for injection - Summary of Product CharacteristicsEMC (UK)
- 2NICE TA1026 recommendations: tirzepatide for managing overweight and obesityNICE
- 3SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff et al, 2022)New England Journal of Medicine / PubMed
- 4SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (Aronne et al, 2025), 20.2% vs 13.7% at week 72New England Journal of Medicine (PubMed)
- 5Tirzepatide - StatPearls (dual GIP/GLP-1 receptor agonist mechanism)StatPearls / NCBI Bookshelf
- 6Gastrointestinal tolerability of tirzepatide in the SURMOUNT-1 to -4 trials (Rubino et al, 2025)Diabetes, Obesity and Metabolism / PMC
- 7SURPASS-CVOT: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes, Nicholls et al, 2025 (non-inferior)New England Journal of Medicine (PubMed)
- 8Mounjaro (tirzepatide) prescribing information: oral hormonal contraceptives and delayed gastric emptyingEli Lilly
- 9Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period (2024)Clinical Gastroenterology and Hepatology



